Format

Send to

Choose Destination
J Surg Oncol. 2016 Jul;114(1):36-43. doi: 10.1002/jso.24266. Epub 2016 Apr 25.

Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.

Author information

1
Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
2
Department of Otolaryngology, Head and Neck Surgery, Ehime University School of Medicine, Toon, Ehime, Japan.
3
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

Abstract

BACKGROUND AND OBJECTIVES:

The immune checkpoint ligand programmed death ligand-1 (PD-L1) is expressed in various carcinomas and allows carcinoma cells to elude the immune system. PD-L1 expression is associated with the response to anti-programmed death 1 (PD-1)/PD-L1 drugs. This study aimed to clarify the relationship between PD-L1 expression and clinicopathological factors of salivary gland carcinomas (SGCs) and identify its clinical significance.

METHODS:

PD-L1 expression was examined by immunohistochemical analysis using a tissue microarray comprised of 219 surgically resected SGC specimens. Detailed clinicopathological factors, including patient outcome, were available for all cases.

RESULTS:

A case showing complete membranous expression of PD-L1 in more than 1% of whole carcinoma cells was considered positive by ROC analysis. A total of 50 (22.8%) patients showed PD-L1 expression in SGC cells. Positive PD-L1 expression was significantly associated with poor disease free survival (P < 0.001) and overall survival (P < 0.001). Multivariate analysis revealed that positive PD-L1 expression was one of the independent predictors for poor disease free survival (hazard ratio = 2.287, 95% confidence interval = 1.24-4.15; P = 0.008).

CONCLUSIONS:

Positive PD-L1 expression was significantly associated with poor disease free survival of SGCs, suggesting that antibody therapies targeting PD-1/PD-L1 may have potential application in SGCs. J. Surg. Oncol. 2016;114:36-43. © 2016 Wiley Periodicals, Inc.

KEYWORDS:

immunotherapy; prognosis; programmed death 1 (PD-1); programmed death ligand-1 (PD-L1); salivary gland carcinoma

PMID:
27111278
DOI:
10.1002/jso.24266
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center